HEALTH PROFESSIONAL · SOURCE READING
Treatment of Childhood Pheochromocytoma and Paraganglioma
Source: Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 9, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Treatment options for childhood paraganglioma and pheochromocytoma include the following:
Surgery.
Chemotherapy for patients with metastatic disease.
High-dose iodine I 131-labeled metaiodobenzylguanidine (131I-MIBG).
Lutetium Lu 177-DOTATATE and Yttrium Y 90-DOTATOC.[1]
Source links and citations
Tyrosine kinase inhibitor therapy (sunitinib and cabozantinib).[1]
Source links and citations
mTOR inhibitors.[1]
Source links and citations
Immunotherapy.[1]
Source links and citations
Treatment of paraganglioma and pheochromocytoma is surgical. For secreting tumors, alpha- and beta-adrenergic blockade must be optimized before surgery. A single-institution study reviewed the experience of laparoscopic partial adrenalectomy for bilateral pheochromocytoma in patients with von Hippel-Lindau disease.[2] In eight patients, all 16 adrenalectomies were performed laparoscopically. Fourteen of the procedures were partial adrenalectomies, and two patients required a contralateral total adrenalectomy because of tumor size and diffuse multinodularity. Two patients had new ipsilateral tumors identified after a median follow-up of 5 years (range, 4–6 years), with one patient who underwent repeat partial adrenalectomy. There were no deaths during the study period.
Source links and citations
For patients with metastatic disease, responses have been documented to some chemotherapeutic regimens such as gemcitabine and docetaxel or different combinations of vincristine, cyclophosphamide, doxorubicin, and dacarbazine.[3-5] Chemotherapy may help alleviate symptoms and facilitate surgery, although its impact on overall survival is less clear.
Responses have also been obtained with high-dose 131I-MIBG and sunitinib.[6,7]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice
Triangle